DNAVision to Offer Ipsogen's Breast Cancer Tests | GenomeWeb
NEW YORK (GenomeWeb News) - Ipsogen said today it has inked a pact with DNAVision that allows DNAVision to offer tests based on Ipsogen’s breast cancer gene profiles in a CLIA environment.
 
Ipsogen has a portfolio of diagnostics for blood cancers that are registered in Europe as IVDs. The company said that the agreement with DNAVision enables it to launch “a new generation of IVD profiling diagnostic products addressing unmet needs in guiding breast cancer therapies.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.